Paradigm for Migraine Patients
|
|
- Edgar Holt
- 5 years ago
- Views:
Transcription
1 June Transforming 14, 2018 the Prevention Treatment Paradigm for Migraine Patients January 2019
2 Forward-Looking Statements This presentation and the accompanying commentary contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include all statements that are not historical facts and typically contain words such as believe, will, may, estimate, continue, anticipate, intend, should, plan, approximately, expect, predict, could, support, potential, opportunity, positive, significant, unique, strong, unmet, need, design, strategy, advance, options, robust, unique, path, milestones, upcoming, enable, ensure, maintain, achieve, sufficient, projected, forecasted, new, sets, establishes, on track, freedom or the negative of these terms or other similar expressions. You should consider forward-looking statements carefully because they discuss future expectations, contain projections of future results of operations or financial condition, or state other forward-looking information. These statements relate to our possible and future results of operations, financial condition, business strategies, development plans, regulatory activities, competitive position, commercial plans, potential growth opportunities and effects of competition and the assumptions that underlie these statements. These forwardlooking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, the risks outlined under the caption Risk Factors set forth in Alder s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2018, which was filed with the Securities and Exchange Commission (SEC) November 5, 2018 and is available on the SEC s website at and in other reports and filings we will make with the SEC from time to time. Forward-looking statements are based on our management s beliefs and assumptions and on information currently available to our management. These statements, like all statements in this presentation, speak only as of the date of this presentation (or an earlier date, where specifically noted), and except as required by law, we undertake no obligation to update or revise these statements in light of future developments. For investor audiences only. 2
3 Alder BioPharmaceuticals Compelling Value Proposition Poised to Transform the Treatment Paradigm for Migraine Prevention LARGE UNDERSERVED MARKET OPPORTUNITY EPTINEZUMAB LEAD CANDIDATE DIFFERENTIATED CLINICAL PROFILE EPTINEZUMAB WELL POSITIONED TO GAIN SIGNIFICANT MARKET SHARE ALD1910 PIPELINE PRODUCT POTENTIAL ALTERNATIVE PATHWAY FOR MIGRAINE PREVENTION 3
4 Migraine is a Serious Debilitating Neurological Disease Most disabling disease of people under the age of 501 Top cause of years lived with a disability during the most productive years, Attacks usually last 4-72 hours2 Depression, anxiety, and sleep disturbances2 are common for those with chronic migraine Symptoms include extreme pain, nausea, vomiting, extreme sensitivities to light and sound, gastrointestinal issues 1Steiner, Per year, $13B lost productivity in U.S million lost work days2 TJ, Stovner, LJ, & Vos, T. The Journal of Headache and Pain (2018) 19:17. Research Foundation. Migraine Facts. Available at: Accessed January 2, Migraine 4
5 U.S. Anti-CGRP Migraine Prevention Forecasted To Be A > $5 Billion Market1 13 Million Patient Candidates Eligible for Migraine Prevention2 Oral preventives fail to meet needs of many patients: Adherence, Safety, Tolerability Issues4 ONLY % 27 of Patients on Migraine Prevention2,3 BOTOX Chronic Migraine Est. 250K-275K patients treated in Newly Launched Anti-CGRP SubQ Products Est k NRx Patients in < 8 months6 1DRG 2018 Migraine Market report. of patients based on Alder estimates using third party publicly available data (US Census Bureau; Migraine Research Foundation; Buse DC, Manack AN, Fanning KM, et al. Chronic migraine prevalence, disability, and sociodemographic factors: Results from the American Migraine Prevalence and Prevention Study. Headache 2012;52: ). 3Data on file Marketscan, September Parsekyan D. Migraine prophylaxis in adult patients. West J Med. 2000;173(5): Estimates based on AGN Q3 public earnings statements. 6IQVIA NPA Weekly through 12/17/18. 2Number 5
6 Patients are Suffering & Need Preventive Medications that Work, and work More Quickly 1 2 % 87 rate effectiveness as important in determining whether they accept treatment (highest-rated) 1 rate fast acting as an important treatment feature when considering migraine prevention 1 79 % 64 % would always choose the most effective option regardless of administration method 1 90 % Say I will never give up fighting to find a solution 1 1 Alder proprietary patient market research, 2017 (N=250). 2 Migraine Research Foundation. Migraine Facts. Available at: Accessed November 19,
7 Alder BioPharmaceuticals Compelling Value Proposition Poised to Transform the Treatment Paradigm for Migraine Prevention LARGE UNDERSERVED MARKET OPPORTUNITY EPTINEZUMAB LEAD CANDIDATE DIFFERENTIATED CLINICAL PROFILE EPTINEZUMAB WELL POSITIONED TO GAIN SIGNIFICANT MARKET SHARE ALD1910 PIPELINE PRODUCT POTENTIAL ALTERNATIVE PATHWAY FOR MIGRAINE PREVENTION 7
8 Eptinezumab Differentiation Designed Into the Molecule Enabling Delivery To Meet Patient Needs Eptinezumab mab Quarterly Infusion High specificity with potent binding affinity to the ligand for rapid suppression of CGRP biology 1 Total administered dose is immediately active to inhibit CGRP with 100% bioavailability 1,2 Eptinezumab s highly competitive clinical profile 1. Baker B, Schaeffler B, Cady R, et al; Rational design of a monoclonal antibody (mab) inhibiting calcitonin gene-related peptide, ALD403 (eptinezumab), intended for the prevention of migraine. Poster presented at the American Academy of Neurology (AAN) 2017 Annual Meeting. 2. As compared to 50% -70% for subcutaneous anti-cgrps; Vu et.al., Pharm Res Sep; 34(9): ; Vermeersch, et al., J Pharmacol Exp Ther 354: , September
9 Completed Pivotal Studies Demonstrated Eptinezumab s Competitive Profile PROMISE 1 in Episodic Migraine Patients (N=888; baseline ~9 migraine days per month) Met primary and key secondary endpoints Safety and tolerability similar to placebo PROMISE 2 in Chronic Migraine Patients (N=1,072; baseline ~16 migraine days per month) Met primary and all key secondary endpoints Safety and tolerability similar to placebo RAPID Preventive benefit onset Day One post-infusion EFFECTIVE 50%, 75% and 100% reductions in migraine days SUSTAINED Efficacy sustained and further improved through repeated quarterly infusions NOTE: Comparisons are not based on data resulting from head-to-head trials and are not direct comparisons of safety or efficacy. Different protocol designs, trial designs, patient selection and populations, number of patients, trial endpoints, trial objectives and other parameters that are not the same between the relevant trials may cause any comparisons of results from different trials to be unreliable. 1. PROMISE 1 efficacy as compared with the best reported Phase 3 clinical data for anti-cgrp mabs as reported in press releases, published literature and product labels, where applicable. 2. PROMISE 2 efficacy as compared with the best reported Phase 3 clinical data for anti-cgrp mabs and onabotulinumtoxina as reported in press releases, published literature and product labels, where applicable. 9
10 Rapid: Statistically Significant Day 1 Onset of Prevention Demonstrated PROMISE 2: Chronic Migraine % of Patients with Migraine, Days % Infusion 1 Patients with Migraine, % 50% 40% 30% Average Daily Baseline Prevalence of Migraine: ~58% Day 1 Reduction in Migraine Prevalence Eptinezumab, 300mg, 52% reduction + Eptinezumab, 100mg, 50% reduction + Placebo 27% reduction 20% Day 0 Day 1 Day 7 Day 14 Day 21 Day 28 + statistically significant; Day 1 prevalence rate comparison between eptinezumab vs. placebo Lipton R et al. A Phase 3 Study to Evaluate Eptinezumab for Preventive Treatment of Chronic Migraine: Results of PROMISE-2 (PRevention Of Migraine via Intravenous eptinezumab Safety and Efficacy-2) Trial. Poster Presentation at the American Headache Society (AHS) 2018 Annual Meeting. June 28 July 1, 2018; San Francisco, CA. 10
11 Effective and Sustained: 50% Responder Rate by Month 1 and Further Improved with Subsequent Infusions PROMISE 2: Chronic Migraine 50% Migraine Responder Rates Eptinezumab 100 mg Eptinezumab 300 mg Placebo 64.0 Patients, %* INFUSION 1 Month 1 INFUSION 1 Months 1-3 INFUSION 2 Months statistically significant Lipton R et al. Eptinezumab for Prevention of Chronic Migraine: Results of 2 Quarterly Intravenous Infusions in the Phase 3 PROMISE-2 (PRevention Of Migraine via Intravenous eptinezumab Safety and Efficacy-2) Trial. Scientific Presentation at the American Headache Society (AHS) 2018 Annual Meeting. June 28 July 1, 2018; San Francisco, CA. 11
12 Effective and Sustained: 75% Responder Rate by Month 1 and Further Improved with Subsequent Infusions PROMISE 2: Chronic Migraine 75% Migraine Responder Rates 50 Eptinezumab 100 mg Eptinezumab 300 mg Placebo Patients, %* INFUSION 1 Month 1 INFUSION 1 Months 1-3 INFUSION 2 Months statistically significant Lipton R et al. Eptinezumab for Prevention of Chronic Migraine: Results of 2 Quarterly Intravenous Infusions in the Phase 3 PROMISE-2 (PRevention Of Migraine via Intravenous eptinezumab Safety and Efficacy-2) Trial. Scientific Presentation at the American Headache Society (AHS) 2018 Annual Meeting. June 28 July 1, 2018; San Francisco, CA. 12
13 Effective and Sustained: Average 100% Responder Rate Month 1 to 3 Further Improved with Subsequent Infusions PROMISE 2: Chronic Migraine 100% Migraine Responder Rates 30 Eptinezumab 100 mg Eptinezumab 300 mg Placebo Patients, %* INFUSION 1 Month 1 INFUSION 1 Months 1-3 INFUSION 2 Months statistically significant (nominal) Lipton R et al. Eptinezumab for Prevention of Chronic Migraine: Results of 2 Quarterly Intravenous Infusions in the Phase 3 PROMISE-2 (PRevention Of Migraine via Intravenous eptinezumab Safety and Efficacy-2) Trial. Scientific Presentation at the American Headache Society (AHS) 2018 Annual Meeting. June 28 July 1, 2018; San Francisco, CA. 13
14 PROMISE 2: Safety Data Consistent with Other Eptinezumab Studies TEAE = Treatment Emergent Adverse Event; * All Serious TEAEs judged unrelated to study drug PROMISE 2: 12-Week Safety Data Eptinezumab 300mg, N=350 n (%) Eptinezumab 100mg, N=356 n (%) Placebo N=366 n (%) Subjects with Any TEAE 155 (44) 136 (38) 144 (39) Subjects with Any Serious TEAE* 3 (<1) 3 (<1) 3 (<1) TEAEs >2% in eptinezumab dose groups Nasopharyngitis 22 (6) 13 (4) 15 (4) Nausea 12 (3) 6 (2) 6 (2) Upper Respiratory Infection 14 (4) 11 (3) 16 (4) Urinary Tract Infection 11 (3) 7 (2) 6 (2) Arthralgia 8 (2) 3 (<1) 3 (<1) Dizziness 9 (3) 5 (1) 4 (1) Anxiety 7 (2) 4 (1) 0 Fatigue 6 (2) 7 (2) 4 (1) Kudrow D et al. Eptinezumab Achieved Reductions in Migraine Activity as Early as Day 1 That Were Sustained Through Week 12: Results From PROMISE-2 (PRevention of Migraine via Intravenous eptinezumab Safety and Efficacy-2) Phase 3 Trial in Chronic Migraine. Poster Presentation at the American Academy of Neurology (AAN) 2018 Annual Meeting. April 21-27, 2018; Los Angeles, CA. 14
15 Eptinezumab Uniquely Competitive Profile (Chronic Migraine Absolute Data 1 ) Efficacy Endpoints Eptinezumab Promise-2 2 Absolute Data Range of Results Chronic Preventive Treatments 1 Absolute data Primary Endpoint: Mean Change from Baseline Monthly Migraine Days Day 1 Reduction in Migraine Risk Months 1-3 >50% Responder Rates Month 1 >75% Responder Rates Months 1-3 >75% Responder Rates -7.7 (100mg) -8.2 (300mg) (Months 1-3) 50% (100mg) 52% (300mg) 57.6% (100mg) 61.4% (300mg) 30.9% (100mg) 36.9% (300mg) 26.7% (100mg) 33.1% (300mg) Not Reported 28% % 4 Not Reported 17% 6-21% 6 NOTE: Comparisons are not based on data resulting from head-to-head trials and are not direct comparisons of safety or efficacy. Different protocol designs, trial designs, patient selection and populations, number of patients, trial endpoints, trial objectives and other parameters that are not the same between the relevant trials may cause any comparisons of results from different trials to be unreliable. 1 Sourced from Aimovig, AJOVY, Emgality and BOTOX product inserts and HCP promotional websites. 2 Data on File, Alder BioPharmaceuticals PROMISE 2 Study 011; Absolute data reported for 300mg and 100mg eptinezumab dose groups. 3 AJOVY (fremanezumab-vfrm) injection Current Prescribing Information. North Wales, PA: Teva Pharmaceuticals USA, Inc. Primary endpoint was reduction in monthly headache days of at least moderate severity (months 1-3). 4 Data at Month 3, Aimovig Prescribing Information. Thousand Oaks, CA: Amgen Inc. and East Hanover, NJ: Novartis Pharmaceuticals Corporation. 5 Emgality [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC. 6 Data at Month 3, Aimovg HCP promotional website referencing Brandes JL, Dolezil D, Freeman MC, et al. Chronic migraine treatment with erenumab: responder rates. Poster presented at: American Headache Society, 59th Annual Scientific Meeting; June 8 11, 2017; Boston, MA. 15
16 Alder BioPharmaceuticals Compelling Value Proposition Poised to Transform the Treatment Paradigm for Migraine Prevention LARGE UNDERSERVED MARKET OPPORTUNITY EPTINEZUMAB LEAD CANDIDATE DIFFERENTIATED CLINICAL PROFILE EPTINEZUMAB WELL POSITIONED TO GAIN SIGNIFICANT MARKET SHARE ALD1910 PIPELINE PRODUCT POTENTIAL ALTERNATIVE PATHWAY FOR MIGRAINE PREVENTION 16
17 HCP Market Research Suggests Eptinezumab Well-Positioned for Adoption HCPs highly rated Eptinezumab on efficacy with 50% / 75% responder rates, reduction in monthly migraine days and rapid onset of effect 2 Procedure-Oriented Headache Specialists, Neurologists, Pain Specialists and PCPs 1 3 in 5 physicians believe less frequent administration and rapid onset of effect are important to anti-cgrp prescribing 2 ~20-30% 45 HCP feedback on % potential eptinezumab share of anti-cgrp market based on clinical profile 2 HCPs are likely to add or expand their IV capabilities 2 1 Alder proprietary physician market research, Alder proprietary ATU physician market research,
18 Specialty Sized Market Poised to Adopt New IV Procedures For Migraine Prevention Distribution of CGRP Rx to date by HCP 120% 100% 50% of scripts written by 820 HCPs 80% of scripts written by 2400 HCPs 20 % % of Business 80% 60% 40% 20% Top 2,432 HCPs (1,490 with infusion procedures) cover 80% CGRP, 43% Oral, 58% Botox 2 Of HCPs have prescribed 80% of anti-cgrp SubQ scripts 2 ~3,000 Procedure-Oriented Headache Specialists Neurologists, Pain Specialists and PCPs 1 See the largest number of highly impacted migraine patients Value patient adherence and product control Value practice economics 0% % Have IV access 1 63% have in-office # of HCPs 77% Have prescribed an IV to their patients access 1 for migraine 1 Specialty Size Sales Force of Alder proprietary physician market research, IQVIA Alder Migraine Target List Study
19 Market Research Suggests Highly Impacted Migraine Patients Prefer Eptinezumab Infusion ~5-7M Highly Impacted Chronic and More Severe Episodic Migraine Patients 1 74 % believe IV medications work the fastest when compared to other injection forms of administration 2 52 % of patients in market research would choose an infusion product with Eptinezumab s profile over a subcutaneous preventive therapy 2 1. Alder estimate of potential U.S. patient population for eptinezumab based on Alder proprietary market research. 2. Alder proprietary patient market research, 2017 (N=250) 19
20 Alder is Uniquely Positioned to Capture High Value Market Opportunity Migraine is a Serious Debilitating Disease Eptinezumab s Differentiated Characteristics2 ~ 3,000 Proceduralist HCP Migraine Specialists RAPID Preventive benefit achieved Day One post-infusion3 US Anti-CGRP Migraine Prevention Forecasted to be a >$5 Billion Market1 EFFECTIVE >50%, >75% and 100% reductions in migraine days SUSTAINED $ DRG 2018 Migraine Market report PROMISE 1 and PROMISE 2 studies 3 Benefit observed within the first infusion period 4 Alder proprietary market research ATU Alder proprietary patient market research, 2017 (N=250) Efficacy sustained for 3 months following a single administration ~20-30% potential Eptinezumab share of anticgrp prevention market4 ~ 5-7M Highly Impacted Chronic and More Severe Episodic Migraine Patients1 52% Of patients would choose Eptinezumab over a subcutaneous therapy5 1 2 Eptinezumab 20
21 Eptinezumab Key Milestones Event Completion PROMISE 1 Episodic Migraine PROMISE 2 Chronic Migraine Open Label Safety Study PK Comparability Study BLA Submission Eptinezumab Anticipated Launch Q Q
22 Alder BioPharmaceuticals Compelling Value Proposition Poised to Transform the Treatment Paradigm for Migraine Prevention LARGE UNDERSERVED MARKET OPPORTUNITY EPTINEZUMAB LEAD CANDIDATE DIFFERENTIATED CLINICAL PROFILE EPTINEZUMAB WELL POSITIONED TO GAIN SIGNIFICANT MARKET SHARE ALD1910 PIPELINE PRODUCT POTENTIAL ALTERNATIVE PATHWAY FOR MIGRAINE PREVENTION 22
23 ALD1910 Aims to Expand Migraine Prevention with Anti-PACAP Antibody PACAP inhibition offers a differentiated and complementary approach to migraine prevention ALD1910 Like CGRP, infusion of PACAP has been shown to induce migraine attacks in migraine patients ~75% 1 Estimated to respond well to eptinezumab (anti-cgrp) 2 Preclinical data indicate that PACAP and CGRP may have non-overlapping pharmacology with 5M respect to migraineassociated symptoms 2,3 ALD1910 is a first-in-class anti-pacap antibody Highly potent and selective humanized antibody Ligand approach allows blockage of the three peripheral PACAP receptors GMP manufacturing and IND-enabling studies underway to support potential 2H2019 IND 1 Schytz et al., Neurotherapeutics 2010; 7(2): Kaiser & Russo, Neuropeptides 2013;47(6): Alder unpublished research demonstrating that PACAP-driven migraine symptoms in rodents are not inhibited by anti-cgrp antibodies ALD1910 is an investigational product and has not been approved by the FDA or any other regulatory body. 23
24 Q Financial Results and Financial Outlook* Q Financial Results Cash position of $484.7M 1 as of Sept 30, cash investment 2 in the range of $250M and $270M Sufficient cash to meet projected operating requirements into 2020 with key activities including: BLA submission and filing Establishment of eptinezumab commercial drug supply chain Continued build out of Alder s commercial organization (e.g., marketing, sales, medical affairs, payor access, IT) Pre-launch market readiness Jan ATM facility established to provide financing optionality 1 Includes cash, cash equivalents, short and long-term investments and restricted cash 2 Net cash used in operating activities plus purchases of property and equipment as defined under U.S. Generally Accepted Accounting Principles. *Outlook as of November 5,
25 June Transforming 14, 2018 the Prevention Treatment Paradigm for Migraine Patients January 2019
26 Appendix 26
27 Rapid: Statistically Significant Day 1 Onset of Prevention Demonstrated PROMISE 1: Episodic Migraine % of Patients with Migraine, Days 1-28 Percent of Patients with Migraine 35% 30% 25% 20% Average (28 day) Baseline Prevalence of Migraine: ~ 30% Infusion 1 Day 1 Reduction in Migraine Prevalence Eptinezumab, 300mg, 55% reduction + Eptinezumab, 100mg, 52% reduction + Placebo 24% reduction 15% 10% Day 0 Day 1 Day 7 Day 14 Day 21 Day 28 + Statistically significant (unadjusted) Silberstein, S et al. Eptinezumab Results for the Prevention of Episodic Migraine Over 1 Year in the PROMISE-1 (PRevention Of Migraine via Intravenous eptinezumab Safety and Efficacy-1) Trial. Poster Presentation at the American Headache Society (AHS) 2018 Annual Scientific Meeting. June 28 July 1, 2018; San Francisco, CA. 27
28 50% Responder Rates by Month 1 Sustained and Further Improved with Subsequent Infusions Baseline: ~8.6 Migraine Days PROMISE 1: Episodic Migraine 50% Migraine Responder Rates 80 Eptinezumab 100 mg Eptinezumab 300 mg Placebo Patients, %* INFUSION 1 Month 1 INFUSION 1 Months 1-3 INFUSION 4 Months statistically significant; + statistically significant (unadjusted); statistically significant (post-hoc) Saper J et al. Neurology. 2018;90(suppl 15):S20. Scientific Platform Presentation by Silberstein S at the American Academy of Neurology (AAN) 2018 Annual Meeting, April 21-27, 2018; Los Angeles, CA Silberstein, S et al. Eptinezumab Results for the Prevention of Episodic Migraine Over 1 Year in the PROMISE-1 (PRevention Of Migraine via Intravenous eptinezumab Safety and Efficacy-1) Trial. Poster Presentation at the American Headache Society (AHS) 2018 Annual Scientific Meeting. June 28 July 1, 2018; San Francisco, CA. 28
29 75% Responder Rates by Month 1 Sustained and Further Improved with Subsequent Infusions Baseline: ~8.6 Migraine Days PROMISE 1: Episodic Migraine 75% Migraine Responder Rates 60 Eptinezumab 100 mg Eptinezumab 300 mg Placebo Patients, %* NS INFUSION 1 Month 1 INFUSION 1 Months 1-3 INFUSION 4 Months statistically significant; statistically significant (post-hoc); NS, not significant Saper J et al. Neurology. 2018;90(suppl 15):S20. Scientific Platform Presentation by Silberstein S at the American Academy of Neurology (AAN) 2018 Annual Meeting, April 21-27, 2018; Los Angeles, CA Silberstein, S et al. Eptinezumab Results for the Prevention of Episodic Migraine Over 1 Year in the PROMISE-1 (PRevention Of Migraine via Intravenous eptinezumab Safety and Efficacy-1) Trial. Poster Presentation at the American Headache Society (AHS) 2018 Annual Scientific Meeting. June 28 July 1, 2018; San Francisco, CA. 29
30 100% Responder Rates by Month 1 Sustained and Further Improved with Subsequent Infusions Baseline: ~8.6 Migraine Days PROMISE 1: Episodic Migraine 100% Migraine Responder Rates 40 Eptinezumab 100 mg Eptinezumab 300 mg Placebo Patients, %* NS INFUSION 1 Month 1 INFUSION 1 Months 1-3 INFUSION 4 Months statistically significant (unadjusted); NS, not significant Average percentage of patients with 100% response at any given month Saper J et al. Neurology. 2018;90(suppl 15):S20. Scientific Platform Presentation by Silberstein S at the American Academy of Neurology (AAN) 2018 Annual Meeting, April 21-27, 2018; Los Angeles, CA Silberstein, S et al. Eptinezumab Results for the Prevention of Episodic Migraine Over 1 Year in the PROMISE-1 (PRevention Of Migraine via Intravenous eptinezumab Safety and Efficacy-1) Trial. Poster Presentation at the American Headache Society (AHS) 2018 Annual Scientific Meeting. June 28 July 1, 2018; San Francisco, CA. 30
Committed to Transforming the Treatment Paradigm for Migraine Prevention
June 14, 2018 Committed to Transforming the Treatment Paradigm for Migraine Prevention September 6, 2018 Forward-Looking Statements This presentation and the accompanying commentary contains certain forward-looking
More informationCommitted to Transforming the Treatment Paradigm for Migraine Prevention
Committed to Transforming the Treatment Paradigm for Migraine Prevention 36th Annual J.P. Morgan Healthcare Conference January 8, 2018 Forward-Looking Statements This presentation and the accompanying
More informationPROMISE 2 Top-Line Data Results January 8, 2018
PROMISE 2 Top-Line Data Results January 8, 2018 Forward-Looking Statements This presentation and the accompanying commentary contains certain forward-looking statements within the meaning of Section 27A
More informationTransforming Treatment for Migraine. 16 th Annual Needham Healthcare Conference April 4, 2017
Transforming Treatment for Migraine 16 th Annual Needham Healthcare Conference April 4, 2017 Forward Looking Statements This presentation and the accompanying commentary contain certain forward-looking
More informationPROMISE 1 Top-Line Data Results. June 27, 2017
PROMISE 1 Top-Line Data Results dd June 27, 2017 Forward Looking Statements This presentation and the accompanying commentary contains certain forward-looking statements within the meaning of Section 27A
More informationRichard B. Lipton, 1 Joel Saper, 2 Messoud Ashina, 3 David Biondi, 4 Suman Bhattacharya, 4 Joe Hirman, 5 Barbara Schaeffler, 4 Roger Cady 4
A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of for the Preventive Treatment of Chronic Migraine: Results of the PROMISE-2 (PRevention Of Migraine via
More informationTargeted Therapeutics for Inflammatory Disease Jefferies Healthcare Conference
Targeted Therapeutics for Inflammatory Disease 2016 Jefferies Healthcare Conference Forward Looking Statements / Safe Harbor This presentation and the accompanying oral commentary contain forward-looking
More informationNovartis announces Phase III STRIVE data published in NEJM demonstrating significant and sustained efficacy of erenumab in migraine prevention
Novartis International AG Novartis Global Communications CH-4002 Basel Switzerland http://www.novartis.com MEDIA RELEASE COMMUNIQUE AUX MEDIAS MEDIENMITTEILUNG Novartis announces Phase III STRIVE data
More informationCGRP, MONOCLONAL ANTIBODIES AND SMALL MOLECULES (-GEPANTS)
CGRP, MONOCLONAL ANTIBODIES AND SMALL MOLECULES (-GEPANTS) Hans-Christoph Diener Senior Professor of Clinical Neurosciences University Duisburg-Essen Germany CGRP, Monoclonal Antibodies and Small Molecules
More informationAquinox Q2 /2015 Conference Call: LEADERSHIP Secondary Endpoint Update - AQX-1125 in BPS/IC. August 6, 2015
Aquinox Q2 /2015 Conference Call: LEADERSHIP Secondary Endpoint Update - AQX-1125 in BPS/IC August 6, 2015 Forward Looking Statements / Safe Harbor This presentation and the accompanying oral commentary
More information1/25/2018 ARE CGRP ANTAGONISTS ANY BETTER THAN CURRENT EVIDENCE BASED TREATMENTS? Disclosures: Objectives: Headache Division
ARE CGRP ANTAGONISTS ANY BETTER THAN CURRENT EVIDENCE BASED TREATMENTS? Lawrence C Newman, MD, FAHS, FAAN Clinical Professor of Neurology Disclosures: Advisory Board: Alder, Allergan, Amgen, Lilly, Supernus,
More informationIdenix Pharmaceuticals Building a Leading Antiviral Franchise. Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston
Idenix Pharmaceuticals Building a Leading Antiviral Franchise Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston Safe Harbor This presentation includes forward-looking statements
More informationBroad and clinically important benefits beyond the initial registrational endpoints are now reported.
Biohaven Announces Robust Clinical Data with Single Dose Rimegepant That Defines Acute and Durable Benefits to Patients: The First Oral CGRP Receptor Antagonist to Deliver Positive Data on Pain Freedom
More informationDiagnostics for the early detection and prevention of colon cancer. Fourth-Quarter 2014 Earnings Call February 24, 2015
Diagnostics for the early detection and prevention of colon cancer Fourth-Quarter 2014 Earnings Call February 24, 2015 Safe Harbor Statement Certain statements made in this presentation contain forward-looking
More informationTargeted Therapeutics for Inflammatory Disease
Targeted Therapeutics for Inflammatory Disease Forward Looking Statements / Safe Harbor This presentation and the accompanying oral commentary contain forward-looking statements that involve substantial
More informationSAKURA 3 Open-Label Phase 3 Safety Study with DaxibotulinumtoxinA for Injection (RT002) for the Treatment of Moderate to Severe Glabellar Lines
SAKURA 3 Open-Label Phase 3 Safety Study with DaxibotulinumtoxinA for Injection (RT002) for the Treatment of Moderate to Severe Glabellar Lines Presented by Dan Browne, Co-Founder, President & CEO, and
More informationInvestor Presentation March 2015
Investor Presentation March 2015 1 Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include forward-looking statements within the
More informationN a s d a q : I N S Y
N a s d a q : I N S Y 0 Safe Harbor Statement This presentation contains both historical information and forward-looking statements. Forward-looking statements are based on management's current expectations
More informationSupernus Pharmaceuticals
Supernus Pharmaceuticals Jefferies 2016 Healthcare Conference May 2016 1 Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include
More informationPage: 1 of 6. Aimovig (erenumab-aooe) injection, Ajovy (fremanezumab-vfrm) injection, Emgality (galcanezumab-gnim)
Page: 1 of 6 Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Last Review Date: November 30, 2018 Description Aimovig (erenumab-aooe) injection, Ajovy (fremanezumab-vfrm)
More informationLEERINK GLOBAL HEALTHCARE CONFERENCE. Marino Garcia EVP, Chief Strategy Officer February 15, 2017
LEERINK GLOBAL HEALTHCARE CONFERENCE Marino Garcia EVP, Chief Strategy Officer February 15, 2017 SAFE HARBOR STATEMENT This presentation and any statements made for and during any presentation or meeting
More informationSynergy Pharmaceuticals TRULANCE (Plecanatide) Receives U.S. FDA Approval for the Treatment of Adults with Chronic Idiopathic Constipation
January 19, 2017 Synergy Pharmaceuticals TRULANCE (Plecanatide) Receives U.S. FDA Approval for the Treatment of Adults with Chronic Idiopathic Constipation NEW YORK--(BUSINESS WIRE)-- Synergy Pharmaceuticals
More informationNASDAQ: ZGNX. Company Presentation. October 2017
NASDAQ: ZGNX Company Presentation October 2017 2 Forward Looking Statement Zogenix cautions you that statements included in this presentation that are not a description of historical facts are forward-looking
More informationInnovation In Ophthalmics
Innovation In Ophthalmics Ophthalmic Innovation Summit @ AAO 2018 October 25, 2018 Mark Iwicki Chairman & CEO, Kala Pharmaceuticals Disclaimers and Notices This presentation contains forward-looking statements
More information37 th Annual J.P. Morgan Healthcare Conference. January 9, 2019
37 th Annual J.P. Morgan Healthcare Conference January 9, 2019 Forward Looking Statement This presentation includes forward-looking statements. All statements, other than statements of historical facts,
More informationJefferies Healthcare Conference
Jefferies Healthcare Conference June 7, 2016 NASDAQ: CHMA Forward-Looking Statements These slides contain forward-looking statements and information. The use of words such as may, might, will, should,
More informationAM-125 : Intranasal Betahistine
AM-125 : Intranasal Betahistine February 3, 2017 NASDAQ: EARS Forward-looking Statements This presentation and the accompanying oral commentary contain forward-looking statements that involve substantial
More informationNovember 2, Q Financial Results
November 2, 2017 Q3 2017 Financial Results Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Steve Kanes, M.D., Ph.D., Chief Medical Officer
More informationSavient's Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
Savient's Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference EAST BRUNSWICK, N.J., Oct 27, 2008 /PRNewswire-FirstCall
More informationSupernus Pharmaceuticals
Supernus Pharmaceuticals Investor Presentation March 2017 1 Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include forward-looking
More informationAugust 7, Q Financial Results
August 7, 2018 Q2 2018 Financial Results 1 Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Steve Kanes, M.D., Ph.D., Chief Medical Officer
More informationDynavax Corporate Presentation
Dynavax Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements, including statements regarding our HEPLISAV-B TM regulatory submissions, product profile,
More informationMerrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference. February 7, 2007
Merrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference February 7, 2007 Information related to forward-looking statements This presentation includes forward-looking statements
More informationLehman Brothers Eighth Annual Global Healthcare Conference March 30, 2005 Bruce A. Peacock President and Chief Executive Officer
Lehman Brothers Eighth Annual Global Healthcare Conference March 30, 2005 Bruce A. Peacock President and Chief Executive Officer 2005 Adolor Corporation. All rights reserved. Safe Harbor Statement This
More informationESTABLISH 2 Top Line Data Release
The Future of Anti-Infectives ESTABLISH 2 Top Line Data Release March 25, 2013 1 Forward Looking Statements Statements contained in this data release regarding matters that are not historical facts are
More informationFebruary 23, Q4 and Year-End 2016 Financial Results
February 23, 2017 Q4 and Year-End 2016 Financial Results 2 RETHINKING CNS Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Jim Doherty, Ph.D.,
More informationTamsulosin Hydrochloride 0.4 mg Capsule
Tamsulosin Hydrochloride 0.4 mg Capsule, Tamsulosin Hydrochloride 0.4 mg Capsule India, Tamsulosin Hydrochloride 0.4 mg Capsule manufacturers India, side effects Tamsulosin Hydrochloride 0.4 mg Capsule
More informationWARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS
June 5, 2018 Synergy Pharmaceuticals Highlights New Data at Digestive Disease Week (DDW) 2018 Linking Uroguanylin Deficiency to Chronic Idiopathic Constipation (CIC) and Irritable Bowel Syndrome with Constipation
More informationUSPSTF Draft Recommendations Investor Call. October 6, 2015
USPSTF Draft Recommendations Investor Call October 6, 2015 v Safe Harbor Statement Certain statements made in this presentation contain forward-looking statements within the meaning of Section 27A of the
More informationCowen Investor Conference March confidently live life with ease
Cowen Investor Conference March 2018 confidently live life with ease Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that could
More informationJefferies Healthcare Conference. June 6, 2018
Jefferies Healthcare Conference June 6, 2018 Forward-Looking Statements and Non-GAAP Financial Information Some statements in this presentation may be forward-looking statements for purposes of the Private
More informationEmisphere Technologies, Inc. Announces 2008 Second Quarter Financial Results
August 11, 2008 Emisphere Technologies, Inc. Announces 2008 Second Quarter Financial Results Conference Call/Webcast to be Held Monday, August 11 at 10:00 AM EDT CEDAR KNOLLS, N.J., Aug 11, 2008 /PRNewswire-FirstCall
More informationARDELYX REPORTS POSITIVE T3MPO-2 PHASE 3 TRIAL RESULTS IN IBS-C
ARDELYX REPORTS POSITIVE T3MPO-2 PHASE 3 TRIAL RESULTS IN IBS-C OCTOBER 11, 2017 NASDAQ: ARDX FORWARD-LOOKING STATEMENTS To the extent that statements contained in this presentation are not descriptions
More informationAdvancing Innovative Therapies for Neurological Diseases
Advancing Innovative Therapies for Neurological Diseases Phase 3 Topline Rimegepant 75 mg Zydis ODT December 03, 2018 NYSE: BHVN 2018 Biohaven Pharmaceuticals. All rights reserved. Disclaimer This presentation
More informationAviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES
Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES October 30, 2017 Safe Harbor This presentation contains forward-looking statements about
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2016 EARNINGS PRESENTATION MARCH 2017 1 Forward-looking statements disclosure This presentation contains
More informationObsEva Reports First Quarter 2018 Financial Results and Provides Business Update
ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update -Key First Quarter 2018 Clinical Milestones Achieved Patient randomization completed in Phase 2b EDELWEISS trial of OBE2109
More informationPATENCY-1 Top-Line Results
PATENCY-1 Top-Line Results December 13, 2016 2016 Proteon Therapeutics, Inc. Cautionary Note Regarding Forward-Looking Statements This presentation contains statements that are, or may be deemed to be,
More informationMarket Potential for MDX Alcobra Investor Breakfast July 15, 2014
Market Potential for MDX Alcobra Investor Breakfast July 15, 2014 Forward Looking Statement This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases,
More informationCorporate Presentation Fourth Quarter 2017
Corporate Presentation Fourth Quarter 2017 November 2017 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationCompany Overview February 26, 2019
Company Overview February 26, 2019 SAFE HARBOR Cautionary Note Regarding Forward-Looking Statements Certain statements in this presentation constitute forward-looking statements, including, without limitation,
More informationSAVARA CORPORATE PRESENTATION (NASDAQ: SVRA) NOVEMBER 2018
SAVARA CORPORATE PRESENTATION (NASDAQ: SVRA) NOVEMBER 2018 SAFE HARBOR STATEMENT Savara Inc. ( Savara or the Company ) cautions you that statements in this presentation that are not a description of historical
More informationPRO 140. First self-administered antibody therapy for HIV in late-stage clinical development. March
PRO 140 First self-administered antibody therapy for HIV in late-stage clinical development March 2018 Forward-Looking Statements This presentation includes forward-looking statements and forward-looking
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationTheravance Announces Positive Results from Phase 1 and Phase 2 Clinical Studies with TD-1211 in Development for Opioid-Induced Constipation
Theravance Announces Positive Results from Phase 1 and Phase 2 Clinical Studies with TD-1211 in Development for Opioid-Induced Constipation TD-1211 Achieves Primary and Secondary Endpoints SOUTH SAN FRANCISCO,
More informationAnnual Stockholder Meeting May 30, confidently live life with ease
Annual Stockholder Meeting May 30, 2018 confidently live life with ease Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that
More informationTonix Pharmaceuticals Reports Top Line Results From Phase 2b BESTFIT Trial of TNX-102 SL in Patients With Fibromyalgia
September 29, 2014 Tonix Pharmaceuticals Reports Top Line Results From Phase 2b BESTFIT Trial of TNX-102 SL in Patients With Fibromyalgia Conference Call Today at 8:30 a.m. ET NEW YORK, Sept. 29, 2014
More informationDetermined to realize a future in which people with cancer live longer and better than ever before Q Conference Call
Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Q1 2016 Conference Call 1 Forward-Looking Statements Disclosure This presentation
More informationDaniel Kassicieh, DO, FAAN
Daniel Kassicieh, DO, FAAN Migraine a Disease Process Migraine is a chronic disease process similar to many other chronic medical conditions Migraine has a low mortality but high morbidity 38 million Americans
More informationHALOZYME REPORTS SECOND QUARTER 2018 RESULTS
Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER
More informationCorporate Presentation August 6, 2015
Corporate Presentation August 6, 2015 Creating the Next Generation of CNS Drugs Forward-Looking Statement This presentation contains forward-looking statements. These statements relate to future events
More informationDeveloping & Commercializing Targeted Small Molecule Drugs in Cancer
Developing & Commercializing Targeted Small Molecule Drugs in Cancer SAFE HARBOR STATEMENT 2 Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationTELECONFERENCE FY February 2015
TELECONFERENCE FY 2014 5 February 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationDavid Zaccardelli, PharmD Chief Executive Officer. J.P. Morgan 37 th Annual Healthcare Conference January 8, 2019
David Zaccardelli, PharmD Chief Executive Officer J.P. Morgan 37 th Annual Healthcare Conference January 8, 2019 Disclaimer Certain information contained in this presentation relates to or is based on
More information4Q and Full Year 2017 Financial Results Call February 7, 2018
4Q and Full Year 2017 Financial Results Call February 7, 2018 Agenda Topic Welcome Opening Remarks 4Q 2017 Results Commercial Progress Question & Answer Speakers Amy Sullivan, SVP, Corporate Affairs Greg
More informationAerpio Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
Aerpio Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy Remains on Track Conference Call
More informationPatrick J. Sullivan Chief Executive Officer. January 9, 2018 Investor Presentation
Patrick J. Sullivan Chief Executive Officer January 9, 2018 Investor Presentation Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations,
More informationJoel R. Saper, 1 Richard B. Lipton, 2 David B. Kudrow, 3 Joe Hirman, 4 David W. Dodick, 5 Stephen Silberstein, 6 George Chakhava, 7 Jeff Smith 8
Primary Results of PROMISE-1 (PRevention Of Migraine via Intravenous eptinezumab Safety and Efficacy 1) Trial: a Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and
More informationCreating a Leading Global HBV Therapeutics Company. ARB-1467 Update Call December 12, 2016
Creating a Leading Global HBV Therapeutics Company ARB-1467 Update Call December 12, 2016 NASDAQ: ABUS www.arbutusbio.com Forward Looking Statements This presentation contains forward-looking statements
More informationCorporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation May 2016 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary contain
More informationCredit Suisse 27 th Annual Healthcare Conference
CHANGING THE COURSE OF HUMAN HEALTH THROUGH BOLD PURSUITS IN SCIENCE Credit Suisse 27 th Annual Healthcare Conference November 14, 2018 Forward-Looking Statements and Adjusted Financial Information This
More informationGenta Incorporated. A Multiproduct Late-Stage Oncology Company
Genta Incorporated A Multiproduct Late-Stage Oncology Company This presentation may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking
More informationMay 10, 2016 Q & Business Update
May 10, 2016 Q1 2016 Thank Financial you Results & Business Update Q1 2016 Financial Results Prepared Remarks Q1 Update Tom Hughes, Ph.D., Chief Executive Officer Clinical Update Dennis Kim, M.D., Chief
More informationStrengthening our global leadership in treatment of addiction. Morgan Stanley Global Healthcare Conference September 13 th and 14 th 2018
Strengthening our global leadership in treatment of addiction Morgan Stanley Global Healthcare Conference September 13 th and 14 th 2018 Forward Looking Statements This presentation contains certain statements
More informationInvestor Overview. March 2019
Investor Overview March 2019 Forward-Looking Statement These slides and the accompanying oral presentation contain forward-looking statements and information. The use of words such as may, might, will,
More informationAdvances in the Treatment of Migraine
Advances in the Treatment of Migraine C. Philip O Carroll, M.D. Director Neurobehavioral Medicine Hoag Neurosciences Institute Guyuron B Headache, 2015;55:1464-1473 I m sorry your head hurts, sweetie.is
More informationNew Ideas. Better Medicines. Third Quarter Financial Results Conference Call
New Ideas. Better Medicines. Third Quarter 2018 Financial Results Conference Call Forward-Looking Statements 2 This presentation contains forward-looking statements that involve substantial risks and uncertainties.
More informationSunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results
Investor and Media Inquiries: David Pitts Argot Partners 212-600-1902 Eric Bjerkholt Sunesis Pharmaceuticals Inc. 650-266-3717 Sunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results SOUTH
More informationINVESTOR PRESENTATION JEFFERIES 2013 HEALTHCARE CONFERENCE. June 2013
INVESTOR PRESENTATION JEFFERIES 2013 HEALTHCARE CONFERENCE June 2013 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events
More informationNASDAQ: CYTR FIGHTING CANCER WITH CUTTING EDGE SCIENCE. Corporate Overview. July 2018
NASDAQ: CYTR Corporate Overview July 2018 CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY
More informationDARA Reports Year-End 2012 Financial Results
April 1, 2013 DARA Reports Year-End 2012 Financial Results Company Provides a Commercial Portfolio and Development Pipeline Business Update RALEIGH, NC -- (MARKETWIRE) -- 04/01/13 -- DARA BioSciences,
More informationAnti-IL-33 (ANB020) Program
Anti-IL-33 (ANB020) Program Phase 2a Peanut Allergy Clinical Trial Interim Data Update March 26 th 2018 NASDAQ: ANAB Safe Harbor Statement This presentation and the accompanying oral presentation contain
More informationJefferies Healthcare Conference June 6, 2018
Jefferies Healthcare Conference June 6, 2018 Forward-Looking Statements Some of the statements included in this presentation, particularly those regarding the commercialization and ongoing clinical development
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Ajovy) Reference Number: CP.PHAR.## Effective Date: 10.30.18 Last Review Date: 02.19 Line of Business: Commercial, TBD HIM*, Medicaid Revision Log See Important Reminder at the end of
More informationUBS Global Healthcare Conference May 19, 2014
UBS Global Healthcare Conference May 19, 2014 Safe Harbor Statement This presentation may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section
More informationBuilding a Stroke Portfolio. June 28, 2018
Building a Stroke Portfolio June 28, 2018 1 Forward-Looking Statements This presentation contains forward-looking statements, including statements relating to: the potential benefits, safety and efficacy
More informationA LOOK AT CGRP INHIBITORS FOR MIGRAINE PREVENTION JUNE 2018
JUNE 2018 Overview: About Migraine WHAT IS MIGRAINE? Migraine is a common, recurrent headache disorder that affects approximately 20% of women and 6-10% of men in the US. Migraine attacks are characterized
More informationCalliditas Therapeutics Q2 Report Webcast August 16, 2018, 10:00 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO
Calliditas Therapeutics Q2 Report 2018 Webcast August 16, 2018, 10:00 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO Disclaimer Important information This presentation may contain certain
More informationAnnual Results 2017 & Business Update 13 April 2018
Annual Results 2017 & Business Update 13 April 2018 1 Disclaimer These slides and the accompanying oral presentation contain forward-looking statements and information. Forward-looking statements are subject
More informationObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update
ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update IMPLANT 4 trial of nolasiban in IVF starting in Q4 2018, European MAA filing expected late 2019 24-week data from Phase
More informationDiagnostics for the early detection and prevention of colon cancer. Leerink Swann Global Health Care Conference February 2015
Diagnostics for the early detection and prevention of colon cancer Leerink Swann Global Health Care Conference February 2015 Safe Harbor Statement Certain statements made in this news release contain forward-looking
More informationCorporate Presentation Asia Investment Series March 2018
Corporate Presentation Asia Investment Series March 2018 Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward-looking" statements within the meaning of the United
More informationBioMarin Pharmaceutical Inc. Conference Call to Discuss Approval of
BioMarin Pharmaceutical Inc. Conference Call to Discuss Approval of For adult patients with PKU who have uncontrolled blood phenylalanine (Phe) concentrations > 600 µmol/l on existing management May 24,
More informationH. LUNDBECK A/S. Teleconference. 10 August PM CET. Financial results Second quarter 2011
H. LUNDBECK A/S Teleconference 10 August 2011-2PM CET Financial results Second quarter 2011 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts
More informationDiagnostics for the early detection and prevention of colon cancer. Publication of DeeP-C Study Data in New England Journal of Medicine March 2014
Diagnostics for the early detection and prevention of colon cancer Publication of DeeP-C Study Data in New England Journal of Medicine March 2014 Safe Harbor Statement Certain statements made in this presentation
More informationCommercial-Stage Bioelectronic Medicine Company 1 st FDA-cleared non-invasive vagus nerve stimulation platform therapy
Commercial-Stage Bioelectronic Medicine Company 1 st FDA-cleared non-invasive vagus nerve stimulation platform therapy 2018 electrocore. All rights reserved. 1 Disclaimer This presentation may contain
More informationREATA PHARMACEUTICALS, INC. ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND AN UPDATE ON DEVELOPMENT PROGRAMS
REATA PHARMACEUTICALS, INC. ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND AN UPDATE ON DEVELOPMENT PROGRAMS IRVING, Texas August 8, 2018 Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage
More information